Loading...
On October 8, 2013, ViiV Healthcare announced (in a pdf provided by the company's regional medical scientists) that a clinical trial comparing maraviroc to tenofovir/FTC was being halted by the study's data-monitoring committee.
The trial, called MODERN (standing for “Maraviroc Once-Daily with Darunavir Enhanced by Ritonavir in a Novel Regimen”), enrolled treatment-naive patients with CCR5-tropic virus. Participants were randomized to maraviroc 150 mg or tenofovir/FTC, both once daily with matching placebos, in addition to once-daily ritonavir-boosted darunavir. In a preliminary analysis of data from 791 patients, 72% of those in the maraviroc arm and 83% of those in the tenofovir/FTC arm had viral loads <50 copies/mL at week 48 (difference,…